EDITORIAL
FOCUS 2
FOREWORD I
’d like to welcome you to our fi rst edition of FOCUS ON LIFE SCIENCES, our new multi-channel magazine for business leaders.
We have curated the content around themes that have emerged from conversations we have had with our global clients over the last twelve months.
The industry backdrop is well known to executives today. We are operating in an increasingly competitive market with pressures angled up and down the value chain: sluggish R&D productivity, patent expiries, tightening regulation, pricing pressures and changing customer demands.
One of the key questions that businesses are trying to answer is how to sustain growth in this challenging environment.
Whilst it probably isn’t a one-size-fi ts-all approach we are seeing a lot of activity in the market as companies try to reorganise their business models to adapt to the changing healthcare landscape and technological evolution.
One tactic is refl ected in the high deal activity which is clearly an important part of the growth strategy for life sciences companies. Another is the attempt to put patients at the centre of their business models – something which we feel companies are really struggling with. Patients have
changed over the last 20 years and are now much more involved in their own care, with 80% going online before they see a doctor. Companies need to think differently about how to engage with this empowered patient.
A potential solution is to look to ‘big data’ and other innovative technologies to collect information to help understand patients better. Similarly, these technologies can be leveraged in other areas. For instance, over the last 50 years there has been an unparalleled rise in R&D spend without a matched increase in productivity. This is particularly frustrating because we are in a period of rapid scientifi c development. Indeed, the pace of change is creating issues of its own, treatments are becoming increasingly personalised and traditional research and bulk manufacturing methods aren’t adapted to deal with this.
© 2014 KPMG LLP, a UK limited liability partnership, and a member fi rm of the KPMG network of independent member fi rms affi liated with KPMG International Cooperative, a Swiss entity. All rights reserved.
We have built our KPMG life sciences team to help clients deal with these issues and have had a number of talented people join us recently. Nathan Beaver comes with industry experience to lead our customer growth and patient centricity team, Dr. Gerald Dunstan, a former pharma R&D scientist, has joined us to lead our life sciences strategy team and John Elliot has joined as a special adviser in supply chain and manufacturing.
We discuss a number of these challenges and solutions in this issue and I hope you enjoy reading it.
Chris Stirling Global Head of Life Sciences
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41